A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Boryung Pharmaceutical Co., Ltd1 site in 1 country9,000 target enrollmentJuly 26, 2023

Overview

The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension

Registry

clinicaltrials.gov

Start Date

July 26, 2023

End Date

October 21, 2025

Last Updated

7 months ago

Study Type

Observational

Sex

All

Sponsor

Responsible Party

Sponsor

•Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
•Those who voluntarily signed a written personal information agreement to participate in this clinical study.
•Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.

•Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
•Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
•Those who are expected to need insulin prescription during the study period
•Pregnant women, breast-feeding women